Immunotherapy has fundamentally redrawn the oncology treatment map over the past decade, yet the specific promise of therapeutic cancer vaccines — designed to train the immune system to recognize and destroy existing tumors rather than prevent infection — has remained tantalizingly just out of reach. A comprehensive review in Acta Pharmacologica Sinica surveys the current developmental terrain, illuminating both the clinical milestones achieved and the structural barriers that continue to slow translation from bench to bedside.
The review synthesizes progress across the major vaccine platform categories: peptide-based constructs, dendritic cell vaccines, viral vectors, DNA and RNA formulations, and emerging neoantigen-targeted approaches. Central to the field's evolution is the shift toward personalized neoantigen vaccines, which exploit tumor-specific mutations to generate highly individualized immune responses. The analysis catalogues key immunological challenges — including tumor-induced immune suppression, antigen heterogeneity within tumors, and inadequate T-cell trafficking into the tumor microenvironment — while mapping active combination strategies pairing vaccines with checkpoint inhibitors, adjuvants, and cytokine modulators.
This review arrives at a genuinely inflection-point moment. mRNA vaccine technology, validated through COVID-19 applications, has dramatically lowered the manufacturing barrier for personalized cancer vaccines; Moderna and Merck's mRNA-4157/V940 neoantigen vaccine showed meaningful recurrence reduction in melanoma Phase IIb data, creating real momentum for larger trials. What this synthesis adds is a structured framework for understanding why certain platforms have advanced while others stall — antigen selection, delivery vehicle immunogenicity, and adjuvant choice emerge as compounding variables that no single trial can optimize simultaneously. For health-conscious adults monitoring the immunotherapy frontier, the practical implication is that therapeutic cancer vaccines are moving from experimental curiosity toward conditional clinical utility, though regulatory approval for most indications remains several trial phases away. The review is appropriately cautious: this is a consolidating, not breakthrough, contribution — useful precisely because it maps the field's gaps as clearly as its achievements.